Developing in vitro models to assess fish gill excretion of emerging contaminants
Developing in vitro models to assess fish gill excretion of emerging contaminants
Advances in analytical methods have enabled the detection of emerging contaminants at ever lower concentrations in freshwaters. However, such measurements need to be linked to effect-based assays to identify risks. The bioconcentration factor (BCF) forms part of a chemical's environmental risk assessment (ERA), and current regulatory testing guidelines to calculate fish BCFs use hundreds of fish per chemical. Due to ethical concerns a reduction in the numbers of animals used is desired, and there is a need to identify in vitro or in silico alternatives which meet regulatory acceptance. This study describes the successful demonstration of a FIsh Gill Cell culture System (FIGCS) to assess an often overlooked parameter in pharmacokinetics: the excretion of drugs across the gill. The FIGCS tolerates the application of natural waters on its apical surface, mimicking the situation of the live fish, and thus in combination with advanced analytical methods, offers an opportunity to take lab-based testing used for ERA, such as compound uptake, biotransformation or excretion directly into field for validation with natural waters. Here we used the basic drug propranolol and the acidic ibuprofen as a demonstration of the FIGCS utility in three separate experiments. Excretion across the apical membrane showed saturation kinetics, suggesting the involvement of carrier-mediated processes. Both propranolol and ibuprofen were excreted across the epithelium from the media (internal blood equivalent) to the water, with ibuprofen excretion being considerably slower than propranolol excretion. Further studies indicate that ibuprofen may be complexing with fetal bovine serum (FBS) reducing bioavailability; in contrast propranolol efflux rate was unaffected, indicating that drugs behave differently in the presence of FBS and other plasma proteins. A key issue in future ERA is to better understand the effects of mixtures of different pollutant classes found in environmental samples, and this model offers an ethical path to do this
1470-1478
Chang, Elisabeth Dohmann
6534712c-d32e-4e61-a112-6752cd89f13e
Owen, Stewart F.
55aee991-6bd9-4535-9ce5-79ab59317ff5
Hogstrand, Christer
157377cc-b2e9-4931-8a88-0b8764362ee5
Bury, Nic R.
696daba0-5cc9-444c-be9a-c678808712c6
2 March 2021
Chang, Elisabeth Dohmann
6534712c-d32e-4e61-a112-6752cd89f13e
Owen, Stewart F.
55aee991-6bd9-4535-9ce5-79ab59317ff5
Hogstrand, Christer
157377cc-b2e9-4931-8a88-0b8764362ee5
Bury, Nic R.
696daba0-5cc9-444c-be9a-c678808712c6
Chang, Elisabeth Dohmann, Owen, Stewart F., Hogstrand, Christer and Bury, Nic R.
(2021)
Developing in vitro models to assess fish gill excretion of emerging contaminants.
Analytical Methods, 2021 (12), .
(doi:10.1039/D0AY02282A).
Abstract
Advances in analytical methods have enabled the detection of emerging contaminants at ever lower concentrations in freshwaters. However, such measurements need to be linked to effect-based assays to identify risks. The bioconcentration factor (BCF) forms part of a chemical's environmental risk assessment (ERA), and current regulatory testing guidelines to calculate fish BCFs use hundreds of fish per chemical. Due to ethical concerns a reduction in the numbers of animals used is desired, and there is a need to identify in vitro or in silico alternatives which meet regulatory acceptance. This study describes the successful demonstration of a FIsh Gill Cell culture System (FIGCS) to assess an often overlooked parameter in pharmacokinetics: the excretion of drugs across the gill. The FIGCS tolerates the application of natural waters on its apical surface, mimicking the situation of the live fish, and thus in combination with advanced analytical methods, offers an opportunity to take lab-based testing used for ERA, such as compound uptake, biotransformation or excretion directly into field for validation with natural waters. Here we used the basic drug propranolol and the acidic ibuprofen as a demonstration of the FIGCS utility in three separate experiments. Excretion across the apical membrane showed saturation kinetics, suggesting the involvement of carrier-mediated processes. Both propranolol and ibuprofen were excreted across the epithelium from the media (internal blood equivalent) to the water, with ibuprofen excretion being considerably slower than propranolol excretion. Further studies indicate that ibuprofen may be complexing with fetal bovine serum (FBS) reducing bioavailability; in contrast propranolol efflux rate was unaffected, indicating that drugs behave differently in the presence of FBS and other plasma proteins. A key issue in future ERA is to better understand the effects of mixtures of different pollutant classes found in environmental samples, and this model offers an ethical path to do this
This record has no associated files available for download.
More information
Published date: 2 March 2021
Additional Information:
Funding for this research was provided by: Biotechnology and Biological Sciences Research Council (BB/M014827/1) AstraZeneca
Identifiers
Local EPrints ID: 475595
URI: http://eprints.soton.ac.uk/id/eprint/475595
ISSN: 1759-9660
PURE UUID: 4a0561ed-3990-4c4b-bf9d-2d4a4a929a0a
Catalogue record
Date deposited: 22 Mar 2023 17:32
Last modified: 17 Mar 2024 04:14
Export record
Altmetrics
Contributors
Author:
Elisabeth Dohmann Chang
Author:
Stewart F. Owen
Author:
Christer Hogstrand
Author:
Nic R. Bury
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics